Analytical Data
-
基因名
HLA-A*02:01&B2M&hTERT(ILAKFLHWL) Monomer
- Application
-
别名
HLA-A*0201 & B2M & hTERT (ILAKFLHWL)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59606.1 (G25-I308)&P61769
-
表达区间
AAA59606.1 (G25-I308)&P61769 (I21-M119)&ILAKFLHWL
-
分子量
42-43 kDa and 10 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01/B2M/hTERT (ILAKFLHWL) monomer recombinant protein has garnered significant attention in immunological and cancer research due to its potential role in tumor immunotherapy. HLA-A*02:01 is one of the most prevalent human major histocompatibility complex (MHC) class I molecules, known for its ability to present specific peptides, thus playing a critical role in T-cell-mediated immune responses. The incorporation of beta-2-microglobulin (B2M) is essential for the stability and functional expression of this MHC class I molecule. The human telomerase reverse transcriptase (hTERT) peptide ILAKFLHWL has been identified as a promising target for tumor-specific T cells, given that hTERT is overexpressed in many cancers but minimally present in normal tissues. The development of a monomeric form of this recombinant protein facilitates in-depth studies of T-cell receptor (TCR) binding and activation, ultimately advancing our understanding of the immune response against hTERT-expressing tumors. Such research could pave the way for new therapeutic strategies, including cancer vaccines and adoptive T-cell therapies, aimed at enhancing anti-tumor immunity and improving clinical outcomes for cancer patients. The precise characterization of this monomeric form is critical for optimizing its application in both basic research and clinical settings, underscoring the relevance of HLA-A*02:01/B2M/hTERT (ILAKFLHWL) as a focal point in the intersection of immunology and oncology.
